Isodiol International Inc. Announces Closing of Strategic Non-Brokered Offering for Total Proceeds of $18 Million

May 28, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and health and wellness products and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, announces the closing of the strategic non-brokered private placement, from May 4, 2018, for total proceeds of $18,000,000.

“We are extremely pleased to close this strategic investment,” said CEO of Isodiol, Marcos Agramont.  “With this additional funding, the Company is now well positioned to further execute its plan of aggressive global expansion and also continue to be a global CBD innovator. International markets present many opportunities for the Company including new market channels, university collaborations, clinical studies, and ultimately increased revenues.”

The Company will use the proceeds of the Private placement primarily for global expansion, including the recently announced expansion in the UK and China.

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

ON BEHALF OF THE BOARD

“Marcos Agramont” CEO & Director

INVESTOR RELATIONS:

[email protected]

Isodiol.com

COMPANY MEDIA :

Isodiol.com
Iso-sport
Potocoffee
BeTru Wellness
C3 Global Biosciences

Join Us On Facebook: https://www.facebook.com/Isodiol/
Twitter: @isodiol

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.